GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » Debt-to-EBITDA

MeiraGTx Holdings (MeiraGTx Holdings) Debt-to-EBITDA : 0.81 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MeiraGTx Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.19 Mil. MeiraGTx Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $85.07 Mil. MeiraGTx Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $110.28 Mil. MeiraGTx Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MeiraGTx Holdings's Debt-to-EBITDA or its related term are showing as below:

MGTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.56   Med: -0.41   Max: 0
Current: -1.56

MGTX's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs MGTX: -1.56

MeiraGTx Holdings Debt-to-EBITDA Historical Data

The historical data trend for MeiraGTx Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MeiraGTx Holdings Debt-to-EBITDA Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.44 -0.41 -0.33 -0.80 -1.56

MeiraGTx Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -0.95 -0.99 -0.60 0.81

Competitive Comparison of MeiraGTx Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, MeiraGTx Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's Debt-to-EBITDA falls into.



MeiraGTx Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MeiraGTx Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.193 + 85.071) / -57.058
=-1.56

MeiraGTx Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.193 + 85.071) / 110.28
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


MeiraGTx Holdings  (NAS:MGTX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


MeiraGTx Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Traded in Other Exchanges
Address
450 East 29th Street, 14th Floor, New York, NY, USA, 10016
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Executives
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc. 10 percent owner 410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson 10 percent owner ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin officer: Chief Medical Officer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin officer: General Counsel and Secretary 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes director, officer: President & CEO C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux officer: Chief Operating Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor director, officer: Chief Dev. Officer C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk director C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman director C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

MeiraGTx Holdings (MeiraGTx Holdings) Headlines

From GuruFocus

MeiraGTx to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 04-20-2023

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

By GuruFocusNews GuruFocusNews 04-19-2022

MeiraGTx Appoints Debra Yu, MD to Board of Directors

By GuruFocusNews GuruFocusNews 04-27-2022